Treatment of Post–Transfusion Graft–versus–Host Disease with Nafmostat Mesilate, a Serine Protease Inhibitor

Abstract

This case indicates that administration of a serine protease inhibitor may improve PT-GVHD symptoms by inhibiting cytotoxic T-cell-mediated killing of target cells in fatal PT-GVHD. Steroids and monoclonal anti-CD3 were probably responsible for the transient clinical improvements. More studies are required, however, on mechanisms to eliminate the donor's lymphocytes.